Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date12 Mar 2024 |
安慰剂对照评价拈痛祛风颗粒治疗急性痛风性关节炎(风湿郁热证)的安全性和有效性的随机双盲多中心临床试验
[Translation] A randomized, double-blind, multicenter clinical trial to evaluate the safety and efficacy of Niantong Qufeng Granules in the treatment of acute gouty arthritis (rheumatic stagnation and heat syndrome) by placebo control
进一步评价拈痛祛风颗粒治疗急性痛风性关节炎(风湿郁热证)的有效性和安全性。
[Translation] To further evaluate the efficacy and safety of Niantong Qufeng Granules in the treatment of acute gouty arthritis (rheumatic depression and heat syndrome).
100 Clinical Results associated with Chengdu Kangrui Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Chengdu Kangrui Pharmaceutical Co., Ltd.
100 Deals associated with Chengdu Kangrui Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Chengdu Kangrui Pharmaceutical Co., Ltd.